Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025)
Kymera Therapeutics (KYMR) posted quarterly Current Deferred Revenue of $34.4 million for Q4 2025, up 153.13% year-over-year from $13.6 million in Q4 2024, and down 7.71% quarter-over-quarter from $37.2 million in Q3 2025.
Kymera Therapeutics (KYMR) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Current Deferred Revenue for 7 consecutive years, with $34.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 153.13% year-over-year to $34.4 million; the TTM figure through Dec 2025 stood at $34.4 million (up 153.13% YoY), while the FY2025 annual figure was $34.4 million, up 153.13% from the prior year.
- Current Deferred Revenue retreated to $34.4 million in Q4 2025 per KYMR's latest filing, from $37.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $152.6 million in Q1 2021 and bottomed at $11.5 million in Q1 2025.
- Historically, Current Deferred Revenue has averaged $55.9 million across 5 years, with a median of $38.6 million in 2025.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue plunged 75.16% — and 2025, when it surged 153.13%.
- Kymera Therapeutics' Current Deferred Revenue stood at $101.0 million in 2021, then sank by 65.1% to $35.3 million in 2022, then surged by 54.99% to $54.7 million in 2023, then slumped by 75.16% to $13.6 million in 2024, then soared by 153.13% to $34.4 million in 2025.
- Business Quant data shows KYMR's Current Deferred Revenue at $34.4 million in Q4 2025, $37.2 million in Q3 2025, and $40.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34.37 Mn |
| Sep 30, 2025 | 37.24 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | 11.48 Mn |
| Dec 31, 2024 | 13.58 Mn |
| Sep 30, 2024 | 20.02 Mn |
| Jun 30, 2024 | 19.26 Mn |
| Mar 31, 2024 | 22.61 Mn |
| Dec 31, 2023 | 54.65 Mn |
| Sep 30, 2023 | 27.35 Mn |
| Jun 30, 2023 | 44.72 Mn |
| Mar 31, 2023 | 32.25 Mn |
| Dec 31, 2022 | 35.26 Mn |
| Sep 30, 2022 | 76.86 Mn |
| Jun 30, 2022 | 83.53 Mn |
| Mar 31, 2022 | 60.85 Mn |
| Dec 31, 2021 | 101.03 Mn |
| Sep 30, 2021 | 116.17 Mn |
| Jun 30, 2021 | 134.94 Mn |
| Mar 31, 2021 | 152.57 Mn |